Search Results for: MAPT

127 interactions involving MAPT - microtubule associated protein tau found:

Sort by: Symbol Number of Pathways Number of Drugs Number of Diseases
Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
CASP8 caspase 8
  • Apoptotic cleavage of cellular proteins
  • Caspase activation via Death Receptors in the presence of ligand
  • NOD1/2 Signaling Pathway
  • TRIF-mediated programmed cell death
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Regulation by c-FLIP
  • RIPK1-mediated regulated necrosis
  • CASP8 activity is inhibited
  • TNFR1-induced proapoptotic signaling
  • Regulation of TNFR1 signaling
  • CLEC7A/inflammasome pathway
  • Regulation of necroptotic cell death
  • Dimerization of procaspase-8
  • Activation, myristolyation of BID and translocation to mitochondria
  • Apoptotic execution phase
  • FasL/ CD95L signaling
  • TRAIL signaling
  • TLR3-mediated TICAM1-dependent programmed cell death
  • NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10
  • Microbial modulation of RIPK1-mediated regulated necrosis
  • Defective RIPK1-mediated regulated necrosis
  • Regulation of NF-kappa B signaling
  • Trichostatin A
  • AN-9
  • Bryostatin 1
  • Bardoxolone
  • Oleandrin
  • Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
CDK1 cyclin dependent kinase 1
  • MAPK3 (ERK1) activation
  • E2F-enabled inhibition of pre-replication complex formation
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of the APC/C
  • Phosphorylation of Emi1
  • Condensation of Prophase Chromosomes
  • MASTL Facilitates Mitotic Progression
  • Resolution of Sister Chromatid Cohesion
  • Condensation of Prometaphase Chromosomes
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Initiation of Nuclear Envelope (NE) Reformation
  • Nuclear Pore Complex (NPC) Disassembly
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Depolymerization of the Nuclear Lamina
  • Anchoring of the basal body to the plasma membrane
  • MAPK6/MAPK4 signaling
  • Ovarian tumor domain proteases
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Degradation
  • Mitotic Prophase
  • G1/S-Specific Transcription
  • Cyclin A/B1/B2 associated events during G2/M transition
  • G2/M DNA replication checkpoint
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Transcriptional regulation by RUNX2
  • PKR-mediated signaling
  • Indirubin-3'-monoxime
  • Olomoucine
  • Hymenialdisine
  • SU9516
  • Alvocidib
  • Alsterpaullone
  • Seliciclib
  • AT-7519
  • Fostamatinib
  • Avotaciclib
CDK2 cyclin dependent kinase 2
  • G0 and Early G1
  • Telomere Extension By Telomerase
  • Activation of ATR in response to replication stress
  • Regulation of APC/C activators between G1/S and early anaphase
  • SCF(Skp2)-mediated degradation of p27/p21
  • Senescence-Associated Secretory Phenotype (SASP)
  • DNA Damage/Telomere Stress Induced Senescence
  • Processing of DNA double-strand break ends
  • TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • G2 Phase
  • Orc1 removal from chromatin
  • Activation of the pre-replicative complex
  • CDK-mediated phosphorylation and removal of Cdc6
  • Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes
  • Cyclin E associated events during G1/S transition
  • Cyclin D associated events in G1
  • Cyclin A/B1/B2 associated events during G2/M transition
  • p53-Dependent G1 DNA Damage Response
  • Cyclin A:Cdk2-associated events at S phase entry
  • PTK6 Regulates Cell Cycle
  • Meiotic recombination
  • Transcriptional regulation of granulopoiesis
  • Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)
  • Regulation of MITF-M-dependent genes involved in cell cycle and proliferation
  • Factors involved in megakaryocyte development and platelet production
  • 4-[5-(Trans-4-Aminocyclohexylamino)-3-Isopropylpyrazolo[1,5-a]Pyrimidin-7-Ylamino]-N,N-Dimethylbenzenesulfonamide
  • Staurosporine
  • Indirubin-3'-monoxime
  • 4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamine
  • Olomoucine
  • 4-[(4-Imidazo[1,2-a]Pyridin-3-Ylpyrimidin-2-Yl)Amino]Benzenesulfonamide
  • 2-Amino-6-Chloropyrazine
  • 6-O-Cyclohexylmethyl Guanine
  • N-[4-(2-Methylimidazo[1,2-a]Pyridin-3-Yl)-2-Pyrimidinyl]Acetamide
  • 1-Amino-6-Cyclohex-3-Enylmethyloxypurine
  • N-(5-Cyclopropyl-1h-Pyrazol-3-Yl)Benzamide
  • Purvalanol
  • [4-(2-Amino-4-Methyl-Thiazol-5-Yl)-Pyrimidin-2-Yl]-(3-Nitro-Phenyl)-Amine
  • (5R)-5-{[(2-Amino-3H-purin-6-yl)oxy]methyl}-2-pyrrolidinone
  • 4-(2,4-Dimethyl-1,3-thiazol-5-yl)-N-[4-(trifluoromethyl)phenyl]-2-pyrimidinamine
  • Hymenialdisine
  • (5-Chloropyrazolo[1,5-a]Pyrimidin-7-Yl)-(4-Methanesulfonylphenyl)Amine
  • 4-(5-Bromo-2-Oxo-2h-Indol-3-Ylazo)-Benzenesulfonamide
  • 4-(2,5-Dichloro-Thiophen-3-Yl)-Pyrimidin-2-Ylamine
  • 4-[(6-Amino-4-Pyrimidinyl)Amino]Benzenesulfonamide
  • 4-[3-Hydroxyanilino]-6,7-Dimethoxyquinazoline
  • SU9516
  • 3-Pyridin-4-Yl-2,4-Dihydro-Indeno[1,2-.C.]Pyrazole
  • Alvocidib
  • (2E,3S)-3-hydroxy-5'-[(4-hydroxypiperidin-1-yl)sulfonyl]-3-methyl-1,3-dihydro-2,3'-biindol-2'(1'H)-one
  • 1-[(2-Amino-6,9-Dihydro-1h-Purin-6-Yl)Oxy]-3-Methyl-2-Butanol
  • 4-((3r,4s,5r)-4-Amino-3,5-Dihydroxy-Hex-1-Ynyl)-5-Fluoro-3-[1-(3-Methoxy-1h-Pyrrol-2-Yl)-Meth-(Z)-Ylidene]-1,3-Dihydro-Indol-2-One
  • Lysine Nz-Carboxylic Acid
  • [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone
  • N'-[4-(2,4-Dimethyl-1,3-thiazol-5-yl)-2-pyrimidinyl]-N-hydroxyimidoformamide
  • N'-(Pyrrolidino[2,1-B]Isoindolin-4-On-8-Yl)-N-(Pyridin-2-Yl)Urea
  • 2-[Trans-(4-Aminocyclohexyl)Amino]-6-(Benzyl-Amino)-9-Cyclopentylpurine
  • 4-[4-(4-Methyl-2-Methylamino-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • 3-[4-(2,4-Dimethyl-Thiazol-5-Yl)-Pyrimidin-2-Ylamino]-Phenol
  • PHENYLAMINOIMIDAZO(1,2-ALPHA)PYRIDINE
  • OLOMOUCINE II
  • TRIAZOLOPYRIMIDINE
  • Seliciclib
  • Bosutinib
  • 4-[(7-OXO-7H-THIAZOLO[5,4-E]INDOL-8-YLMETHYL)-AMINO]-N-PYRIDIN-2-YL-BENZENESULFONAMIDE
  • (13R,15S)-13-METHYL-16-OXA-8,9,12,22,24-PENTAAZAHEXACYCLO[15.6.2.16,9.1,12,15.0,2,7.0,21,25]HEPTACOSA-1(24),2,4,6,17(25),18,20-HEPTAENE-23,26-DIONE
  • N-(3-cyclopropyl-1H-pyrazol-5-yl)-2-(2-naphthyl)acetamide
  • 2-ANILINO-6-CYCLOHEXYLMETHOXYPURINE
  • 1-(5-OXO-2,3,5,9B-TETRAHYDRO-1H-PYRROLO[2,1-A]ISOINDOL-9-YL)-3-(5-PYRROLIDIN-2-YL-1H-PYRAZOL-3-YL)-UREA
  • (5-phenyl-7-(pyridin-3-ylmethylamino)pyrazolo[1,5-a]pyrimidin-3-yl)methanol
  • 2-(3,4-DIHYDROXYPHENYL)-8-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-3-HYDROXY-6-METHYL-4H-CHROMEN-4-ONE
  • (2R)-1-(DIMETHYLAMINO)-3-{4-[(6-{[2-FLUORO-5-(TRIFLUOROMETHYL)PHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENOXY}PROPAN-2-OL
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)-3-thiocyanatopyrazolo[1,5-a]pyrimidin-7-amine
  • O6-CYCLOHEXYLMETHOXY-2-(4'-SULPHAMOYLANILINO) PURINE
  • (2S)-N-[(3E)-5-Cyclopropyl-3H-pyrazol-3-ylidene]-2-[4-(2-oxo-1-imidazolidinyl)phenyl]propanamide
  • 5-[(2-AMINOETHYL)AMINO]-6-FLUORO-3-(1H-PYRROL-2-YL)BENZO[CD]INDOL-2(1H)-ONE
  • N-cyclopropyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine
  • 3-((3-bromo-5-o-tolylpyrazolo[1,5-a]pyrimidin-7-ylamino)methyl)pyridine 1-oxide
  • 6-CYCLOHEXYLMETHOXY-2-(3'-CHLOROANILINO) PURINE
  • 3-bromo-5-phenyl-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • N-[5-(1,1-DIOXIDOISOTHIAZOLIDIN-2-YL)-1H-INDAZOL-3-YL]-2-(4-PIPERIDIN-1-YLPHENYL)ACETAMIDE
  • (3R)-3-(aminomethyl)-9-methoxy-1,2,3,4-tetrahydro-5H-[1]benzothieno[3,2-e][1,4]diazepin-5-one
  • 5-[5,6-BIS(METHYLOXY)-1H-BENZIMIDAZOL-1-YL]-3-{[1-(2-CHLOROPHENYL)ETHYL]OXY}-2-THIOPHENECARBOXAMIDE
  • 5-Bromoindirubin
  • (2S)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (2R)-1-{4-[(4-Anilino-5-bromo-2-pyrimidinyl)amino]phenoxy}-3-(dimethylamino)-2-propanol
  • (5E)-2-Amino-5-(2-pyridinylmethylene)-1,3-thiazol-4(5H)-one
  • 4-{5-[(Z)-(2,4-DIOXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]-2-FURYL}-N-METHYLBENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}-2-(TRIFLUOROMETHYL)BENZENESULFONAMIDE
  • 4-{5-[(Z)-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)METHYL]FURAN-2-YL}BENZOIC ACID
  • 4-{5-[(1Z)-1-(2-IMINO-4-OXO-1,3-THIAZOLIDIN-5-YLIDENE)ETHYL]-2-FURYL}BENZENESULFONAMIDE
  • N-[4-(2,4-DIMETHYL-THIAZOL-5-YL)-PYRIMIDIN-2-YL]-N',N'-DIMETHYL-BENZENE-1,4-DIAMINE
  • (5Z)-5-(3-BROMOCYCLOHEXA-2,5-DIEN-1-YLIDENE)-N-(PYRIDIN-4-YLMETHYL)-1,5-DIHYDROPYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE
  • 6-(3,4-DIHYDROXYBENZYL)-3-ETHYL-1-(2,4,6-TRICHLOROPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
  • 6-(3-AMINOPHENYL)-N-(TERT-BUTYL)-2-(TRIFLUOROMETHYL)QUINAZOLIN-4-AMINE
  • 2-(4-(AMINOMETHYL)PIPERIDIN-1-YL)-N-(3_CYCLOHEXYL-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)ACETAMIDE
  • 1-(3-(2,4-DIMETHYLTHIAZOL-5-YL)-4-OXO-2,4-DIHYDROINDENO[1,2-C]PYRAZOL-5-YL)-3-(4-METHYLPIPERAZIN-1-YL)UREA
  • 4-{[5-(CYCLOHEXYLMETHOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLAMINO)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • 4-({5-[(4-AMINOCYCLOHEXYL)AMINO][1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[5-(CYCLOHEXYLOXY)[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-7-YL]AMINO}BENZENESULFONAMIDE
  • CAN-508
  • (2R)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2S)-1-[4-({4-[(2,5-Dichlorophenyl)amino]-2-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • (2R)-1-[4-({6-[(2,6-Difluorophenyl)amino]-4-pyrimidinyl}amino)phenoxy]-3-(dimethylamino)-2-propanol
  • N-(2-METHOXYETHYL)-4-({4-[2-METHYL-1-(1-METHYLETHYL)-1H-IMIDAZOL-5-YL]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE
  • 4-{[4-(1-CYCLOPROPYL-2-METHYL-1H-IMIDAZOL-5-YL)PYRIMIDIN-2-YL]AMINO}-N-METHYLBENZENESULFONAMIDE
  • 1-(3,5-DICHLOROPHENYL)-5-METHYL-1H-1,2,4-TRIAZOLE-3-CARBOXYLIC ACID
  • (2S)-1-(Dimethylamino)-3-(4-{[4-(2-methylimidazo[1,2-a]pyridin-3-yl)-2-pyrimidinyl]amino}phenoxy)-2-propanol
  • N-(4-{[(3S)-3-(dimethylamino)pyrrolidin-1-yl]carbonyl}phenyl)-5-fluoro-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
  • 2-{4-[4-({4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl}amino)phenyl]piperazin-1-yl}-2-oxoethanol
  • N-[3-(1H-BENZIMIDAZOL-2-YL)-1H-PYRAZOL-4-YL]BENZAMIDE
  • RO-4584820
  • N-Methyl-4-{[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}benzenesulfonamide
  • N-methyl-{4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl}methanesulfonamide
  • 3-{[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene}-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
  • 4-{[(2-Oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino}-N-(1,3-thiazol-2-yl)benzenesulfonamide
  • 3-{[4-([amino(imino)methyl]aminosulfonyl)anilino]methylene}-2-oxo-2,3-dihydro-1H-indole
  • 5-hydroxynaphthalene-1-sulfonamide
  • N-(4-sulfamoylphenyl)-1H-indazole-3-carboxamide
  • 4-[(6-chloropyrazin-2-yl)amino]benzenesulfonamide
  • N-phenyl-1H-pyrazole-3-carboxamide
  • 4-(acetylamino)-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • (4E)-N-(4-fluorophenyl)-4-[(phenylcarbonyl)imino]-4H-pyrazole-3-carboxamide
  • {[(2,6-difluorophenyl)carbonyl]amino}-N-(4-fluorophenyl)-1H-pyrazole-3-carboxamide
  • 5-chloro-7-[(1-methylethyl)amino]pyrazolo[1,5-a]pyrimidine-3-carbonitrile
  • 5-[(4-AMINOCYCLOHEXYL)AMINO]-7-(PROPAN-2-YLAMINO)PYRAZOLO[1,5-A]PYRIMIDINE-3-CARBONITRILE
  • 4-{[(2,6-difluorophenyl)carbonyl]amino}-N-[(3S)-piperidin-3-yl]-1H-pyrazole-3-carboxamide
  • AT-7519
  • 4-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • 4-(4-propoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-2-amine
  • HYDROXY(OXO)(3-{[(2Z)-4-[3-(1H-1,2,4-TRIAZOL-1-YLMETHYL)PHENYL]PYRIMIDIN-2(5H)-YLIDENE]AMINO}PHENYL)AMMONIUM
  • 4-Methyl-5-[(2Z)-2-{[4-(4-morpholinyl)phenyl]imino}-2,5-dihydro-4-pyrimidinyl]-1,3-thiazol-2-amine
  • 6-CYCLOHEXYLMETHYLOXY-2-(4'-HYDROXYANILINO)PURINE
  • 4-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)--BENZAMIDE
  • 6-(CYCLOHEXYLMETHOXY)-8-ISOPROPYL-9H-PURIN-2-AMINE
  • 3-(6-CYCLOHEXYLMETHOXY-9H-PURIN-2-YLAMINO)-BENZENESULFONAMIDE
  • (2R)-2-{[4-(benzylamino)-8-(1-methylethyl)pyrazolo[1,5-a][1,3,5]triazin-2-yl]amino}butan-1-ol
  • 3-({2-[(4-{[6-(CYCLOHEXYLMETHOXY)-9H-PURIN-2-YL]AMINO}PHENYL)SULFONYL]ETHYL}AMINO)PROPAN-1-OL
  • 6-CYCLOHEXYLMETHYLOXY-5-NITROSO-PYRIMIDINE-2,4-DIAMINE
  • 1-methyl-8-(phenylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxylic acid
  • 6-BROMO-13-THIA-2,4,8,12,19-PENTAAZATRICYCLO[12.3.1.1~3,7~]NONADECA-1(18),3(19),4,6,14,16-HEXAENE 13,13-DIOXIDE
  • (2R)-2-({9-(1-methylethyl)-6-[(4-pyridin-2-ylbenzyl)amino]-9H-purin-2-yl}amino)butan-1-ol
  • 1-[4-(AMINOSULFONYL)PHENYL]-1,6-DIHYDROPYRAZOLO[3,4-E]INDAZOLE-3-CARBOXAMIDE
  • 5-(2,3-dichlorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 6-(2-fluorophenyl)-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 3-methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyrazin-8-amine
  • 5-(2-fluorophenyl)-N-(pyridin-4-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 3-bromo-5-phenyl-N-(pyrimidin-5-ylmethyl)pyrazolo[1,5-a]pyridin-7-amine
  • 3-bromo-6-phenyl-N-(pyrimidin-5-ylmethyl)imidazo[1,2-a]pyridin-8-amine
  • N-((2-aminopyrimidin-5-yl)methyl)-5-(2,6-difluorophenyl)-3-ethylpyrazolo[1,5-a]pyrimidin-7-amine
  • 3-cyclopropyl-5-phenyl-N-(pyridin-3-ylmethyl)pyrazolo[1,5-a]pyrimidin-7-amine
  • 4-{[4-AMINO-6-(CYCLOHEXYLMETHOXY)-5-NITROSOPYRIMIDIN-2-YL]AMINO}BENZAMIDE
  • 4-[(5-ISOPROPYL-1,3-THIAZOL-2-YL)AMINO]BENZENESULFONAMIDE
  • N-(5-Isopropyl-thiazol-2-YL)-2-pyridin-3-YL-acetamide
  • Variolin B
  • N(6)-dimethylallyladenine
  • Trilaciclib
CDK5 cyclin dependent kinase 5
  • DARPP-32 events
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • Regulation of TP53 Activity through Phosphorylation
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • NGF-stimulated transcription
  • Activated NTRK2 signals through CDK5
  • NPAS4 regulates expression of target genes
  • Factors involved in megakaryocyte development and platelet production
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK
  • Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
  • Indirubin-3'-monoxime
  • Olomoucine
  • Hymenialdisine
  • SU9516
  • Alvocidib
  • Alsterpaullone
  • 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
  • Trilaciclib
CDK5R1 cyclin dependent kinase 5 regulatory subunit 1
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • Regulation of TP53 Activity through Phosphorylation
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • Activated NTRK2 signals through CDK5
  • NPAS4 regulates expression of target genes
  • Indirubin-3'-monoxime
  • 6-PHENYL[5H]PYRROLO[2,3-B]PYRAZINE
CHEK1 checkpoint kinase 1
  • Signaling by SCF-KIT
  • Activation of ATR in response to replication stress
  • Processing of DNA double-strand break ends
  • Presynaptic phase of homologous DNA pairing and strand exchange
  • TP53 Regulates Transcription of DNA Repair Genes
  • Regulation of TP53 Activity through Phosphorylation
  • G2/M DNA damage checkpoint
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Transcriptional Regulation by E2F6
  • XL844
  • Enzastaurin
  • CHIR-124
  • N-{5-[4-(4-METHYLPIPERAZIN-1-YL)PHENYL]-1H-PYRROLO[2,3-B]PYRIDIN-3-YL}NICOTINAMIDE
  • 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE
  • 2,2'-{[9-(HYDROXYIMINO)-9H-FLUORENE-2,7-DIYL]BIS(OXY)}DIACETIC ACID
  • (2S)-1-AMINO-3-[(5-NITROQUINOLIN-8-YL)AMINO]PROPAN-2-OL
  • 2-(cyclohexylamino)benzoic acid
  • 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)-1H-INDAZOLE-6-CARBONITRILE
  • (3Z)-6-(4-HYDROXY-3-METHOXYPHENYL)-3-(1H-PYRROL-2-YLMETHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE
  • 5-ETHYL-3-METHYL-1,5-DIHYDRO-4H-PYRAZOLO[4,3-C]QUINOLIN-4-ONE
  • (5-{3-[5-(PIPERIDIN-1-YLMETHYL)-1H-INDOL-2-YL]-1H-INDAZOL-6-YL}-2H-1,2,3-TRIAZOL-4-YL)METHANOL
  • 1-(5-CHLORO-2-METHOXYPHENYL)-3-{6-[2-(DIMETHYLAMINO)-1-METHYLETHOXY]PYRAZIN-2-YL}UREA
  • (3-ENDO)-8-METHYL-8-AZABICYCLO[3.2.1]OCT-3-YL 1H-PYRROLO[2,3-B]PYRIDINE-3-CARBOXYLATE
  • 18-CHLORO-11,12,13,14-TETRAHYDRO-1H,10H-8,4-(AZENO)-9,15,1,3,6-BENZODIOXATRIAZACYCLOHEPTADECIN-2-ONE
  • 1-(5-CHLORO-2,4-DIMETHOXYPHENYL)-3-(5-CYANOPYRAZIN-2-YL)UREA
  • 4-(6-{[(4-METHYLCYCLOHEXYL)AMINO]METHYL}-1,4-DIHYDROINDENO[1,2-C]PYRAZOL-3-YL)BENZOIC ACID
  • 4-[3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOL-6-YL]-2-METHOXYPHENOL
  • (2R)-1-[(5,6-DIPHENYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)AMINO]PROPAN-2-OL
  • (2R)-3-{[(4Z)-5,6-DIPHENYL-6,7-DIHYDRO-4H-PYRROLO[2,3-D]PYRIMIDIN-4-YLIDENE]AMINO}PROPANE-1,2-DIOL
  • N-(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)GLYCINE
  • (5,6-DIPHENYL-FURO[2,3-D]PYRIMIDIN-4-YLAMINO)-ACETIC
  • 3-AMINO-3-BENZYL-[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE
  • 3-(1H-BENZIMIDAZOL-2-YL)-1H-INDAZOLE
  • 2-[5,6-BIS-(4-METHOXY-PHENYL)-FURO[2,3-D]PYRIMIDIN-4-YLAMINO]-ETHANOL
  • 2-[(5,6-DIPHENYLFURO[2,3-D]PYRIMIDIN-4-YL)AMINO]ETHANOL
  • REL-(9R,12S)-9,10,11,12-TETRAHYDRO-9,12-EPOXY-1H-DIINDOLO[1,2,3-FG:3',2',1'-KL]PYRROLO[3,4-I][1,6]BENZODIAZOCINE-1,3(2H)-DIONE
  • 1-[(2S)-4-(5-phenyl-1H-pyrazolo[3,4-b]pyridin-4-yl)morpholin-2-yl]methanamine
  • N-(4-OXO-5,6,7,8-TETRAHYDRO-4H-[1,3]THIAZOLO[5,4-C]AZEPIN-2-YL)ACETAMIDE
  • 5,6,7,8-TETRAHYDRO[1]BENZOTHIENO[2,3-D]PYRIMIDIN-4(3H)-ONE
  • [4-amino-2-(tert-butylamino)-1,3-thiazol-5-yl](phenyl)methanone
  • 2-(methylsulfanyl)-5-(thiophen-2-ylmethyl)-1H-imidazol-4-ol
  • 6-MORPHOLIN-4-YL-9H-PURINE
  • 1-[(2S)-4-(5-BROMO-1H-PYRAZOLO[3,4-B]PYRIDIN-4-YL)MORPHOLIN-2-YL]METHANAMINE
  • Prexasertib
  • Fostamatinib
  • LY-2608204
  • PF-477736
CHEK2 checkpoint kinase 2
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
  • Regulation of TP53 Activity through Phosphorylation
  • Regulation of TP53 Degradation
  • Regulation of TP53 Activity through Methylation
  • G2/M DNA damage checkpoint
  • Stabilization of p53
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • XL844
  • Enzastaurin
  • Fostamatinib
  • Li-Fraumeni syndrome, including: Classic Li-Fraumeni syndrome (LFS); LFS-like syndrome (LFSL)
CREBBP CREB binding lysine acetyltransferase
  • Regulation of gene expression by Hypoxia-inducible Factor
  • BMAL1:CLOCK,NPAS2 activates circadian expression
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Transcriptional activation of mitochondrial biogenesis
  • Activation of gene expression by SREBF (SREBP)
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • HATs acetylate histones
  • Attenuation phase
  • Notch-HLH transcription pathway
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • Regulation of lipid metabolism by PPARalpha
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • CD209 (DC-SIGN) signaling
  • TP53 Regulates Transcription of Genes Involved in Cytochrome C Release
  • Activation of the TFAP2 (AP-2) family of transcription factors
  • RUNX1 regulates transcription of genes involved in differentiation of myeloid cells
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • FOXO-mediated transcription of cell death genes
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • SARS-CoV-2 activates/modulates innate and adaptive immune responses
  • Cytoprotection by HMOX1
  • Heme signaling
  • Nuclear events mediated by NFE2L2
  • NPAS4 regulates expression of target genes
  • Formation of paraxial mesoderm
  • NFE2L2 regulating inflammation associated genes
  • NFE2L2 regulating anti-oxidant/detoxification enzymes
  • NFE2L2 regulates pentose phosphate pathway genes
  • NFE2L2 regulating tumorigenic genes
  • NFE2L2 regulating MDR associated enzymes
  • NFE2L2 regulating ER-stress associated genes
  • Regulation of NFE2L2 gene expression
  • Regulation of NFE2L2 gene expression
  • Zygotic genome activation (ZGA)
  • Evasion by RSV of host interferon responses
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes
  • Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters
  • The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
  • Colforsin
  • 9-ACETYL-2,3,4,9-TETRAHYDRO-1H-CARBAZOL-1-ONE
  • Rubinstein-Taybi syndrome
CSNK2A1 casein kinase 2 alpha 1
  • Synthesis of PC
  • WNT mediated activation of DVL
  • Condensation of Prometaphase Chromosomes
  • Signal transduction by L1
  • Regulation of TP53 Activity through Phosphorylation
  • Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding
  • Receptor Mediated Mitophagy
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • Regulation of PTEN stability and activity
  • KEAP1-NFE2L2 pathway
  • Regulation of CDH1 posttranslational processing and trafficking to plasma membrane
  • Maturation of hRSV A proteins
  • SPOP-mediated proteasomal degradation of PD-L1(CD274)
  • Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK
  • Phosphorylation and nuclear translocation of the CRY:PER:kinase complex
  • ATP
  • (5-hydroxyindolo[1,2-a]quinazolin-7-yl)acetic acid
  • 1,8-Di-Hydroxy-4-Nitro-Xanthen-9-One
  • Resveratrol
  • 1,8-Di-Hydroxy-4-Nitro-Anthraquinone
  • Benzamidine
  • 5,8-Di-Amino-1,4-Dihydroxy-Anthraquinone
  • Quercetin
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • Tetrabromo-2-Benzotriazole
  • DIMETHYL-(4,5,6,7-TETRABROMO-1H-BENZOIMIDAZOL-2-YL)-AMINE
  • S-METHYL-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • N1,N2-ETHYLENE-2-METHYLAMINO-4,5,6,7-TETRABROMO-BENZIMIDAZOLE
  • Emodin
  • 3,8-DIBROMO-7-HYDROXY-4-METHYL-2H-CHROMEN-2-ONE
  • 19-(cyclopropylamino)-4,6,7,15-tetrahydro-5H-16,1-(azenometheno)-10,14-(metheno)pyrazolo[4,3-o][1,3,9]triazacyclohexadecin-8(9H)-one
  • N,N'-DIPHENYLPYRAZOLO[1,5-A][1,3,5]TRIAZINE-2,4-DIAMINE
  • 4-(2-(1H-IMIDAZOL-4-YL)ETHYLAMINO)-2-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(CYCLOHEXYLMETHYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-CHLOROBENZYLAMINO)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • 2-(4-ETHYLPIPERAZIN-1-YL)-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZINE-8-CARBONITRILE
  • N-(3-(8-CYANO-4-(PHENYLAMINO)PYRAZOLO[1,5-A][1,3,5]TRIAZIN-2-YLAMINO)PHENYL)ACETAMIDE
  • Dichlororibofuranosylbenzimidazole
  • Quinalizarin
  • Ellagic acid
  • Fostamatinib
CTSD cathepsin D
  • Collagen degradation
  • Metabolism of Angiotensinogen to Angiotensins
  • MHC class II antigen presentation
  • Neutrophil degranulation
  • Insulin receptor recycling
  • Estrogen-dependent gene expression
  • S-Methylcysteine
  • 1h-Benoximidazole-2-Carboxylic Acid
  • 2-Morpholinoethylamine
  • 5-Amino-6-cyclohexyl-4-hydroxy-2-isobutyl-hexanoic acid
  • CYCLOHEXYLMETHYL-2,3-DIHYDROXY-5-METHYL-HEXYLAMIDE
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
  • Neuronal ceroid lipofuscinosis, including: Infantile Neuronal Ceroid Lipofuscinosis (INCL)/ Santavuori-Haltia Disease (CLN1); Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL)/ Jansky-Bielschowsky Disease (CLN2); Juvenile Neuronal Ceroid Lipofuscinosis (JNCL)/Batten Disease/ Spielmeyer-Vogt Disease (CLN3); Adult Neuronal Ceroid Lipofuscinosis (ANCL)/ Kufs Disease (CLN4); LINCL variant (CLN5, CLN6, CLN7, CLN8); Batten Disease variant (CLN9); Congenital NCL (CLN10)
DUSP1 dual specificity phosphatase 1
  • RAF-independent MAPK1/3 activation
  • Negative regulation of MAPK pathway
DYRK1A dual specificity tyrosine phosphorylation regulated kinase 1A
  • G0 and Early G1
  • N-(5-{[(2S)-4-amino-2-(3-chlorophenyl)butanoyl]amino}-1H-indazol-3-yl)benzamide
  • Fostamatinib
DYRK2 dual specificity tyrosine phosphorylation regulated kinase 2
  • Regulation of TP53 Activity through Phosphorylation
EGFR epidermal growth factor receptor
  • Signaling by ERBB2
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Signaling by ERBB4
  • SHC1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • PLCG1 events in ERBB2 signaling
  • PIP3 activates AKT signaling
  • Signaling by EGFR
  • GRB2 events in EGFR signaling
  • GAB1 signalosome
  • SHC1 events in EGFR signaling
  • EGFR downregulation
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • EGFR interacts with phospholipase C-gamma
  • EGFR Transactivation by Gastrin
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Signal transduction by L1
  • Constitutive Signaling by EGFRvIII
  • Inhibition of Signaling by Overexpressed EGFR
  • RAF/MAP kinase cascade
  • ERBB2 Regulates Cell Motility
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • ERBB2 Activates PTK6 Signaling
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • PTK6 promotes HIF1A stabilization
  • Downregulation of ERBB2 signaling
  • TFAP2 (AP-2) family regulates transcription of growth factors and their receptors
  • Extra-nuclear estrogen signaling
  • NOTCH3 Activation and Transmission of Signal to the Nucleus
  • HCMV Early Events
  • Estrogen-dependent nuclear events downstream of ESR-membrane signaling
  • Signaling by ERBB2 KD Mutants
  • Signaling by ERBB2 ECD mutants
  • Signaling by ERBB2 TMD/JMD mutants
  • Respiratory syncytial virus (RSV) attachment and entry
  • Developmental Lineage of Mammary Gland Myoepithelial Cells
  • Cetuximab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Alvocidib
  • IGN311
  • Matuzumab
  • Vandetanib
  • Rindopepimut
  • Canertinib
  • Pelitinib
  • Varlitinib
  • AV-412
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • PD-168393
  • Afatinib
  • Osimertinib
  • Necitumumab
  • Foreskin keratinocyte (neonatal)
  • Depatuxizumab mafodotin
  • Icotinib
  • Neratinib
  • Dacomitinib
  • Fostamatinib
  • Poziotinib
  • Zalutumumab
  • Brigatinib
  • Olmutinib
  • Zanubrutinib
  • Abivertinib
  • Mobocertinib
  • Almonertinib
  • Amivantamab
  • Laryngeal cancer
  • Cervical cancer
  • Oral cancer
  • Gastric cancer
  • Choriocarcinoma
  • Esophageal cancer
  • Glioma
  • Bladder cancer
EP300 EP300 lysine acetyltransferase
  • Regulation of gene expression by Hypoxia-inducible Factor
  • Polo-like kinase mediated events
  • Pre-NOTCH Transcription and Translation
  • Pre-NOTCH Transcription and Translation
  • PPARA activates gene expression
  • PPARA activates gene expression
  • Formation of the beta-catenin:TCF transactivating complex
  • Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells
  • NOTCH1 Intracellular Domain Regulates Transcription
  • NOTCH1 Intracellular Domain Regulates Transcription
  • SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
  • NOTCH2 intracellular domain regulates transcription
  • Constitutive Signaling by NOTCH1 PEST Domain Mutants
  • Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • HATs acetylate histones
  • Attenuation phase
  • Transcriptional regulation of white adipocyte differentiation
  • Transcriptional regulation of white adipocyte differentiation
  • SUMOylation of transcription cofactors
  • B-WICH complex positively regulates rRNA expression
  • Activation of anterior HOX genes in hindbrain development during early embryogenesis
  • CD209 (DC-SIGN) signaling
  • Metalloprotease DUBs
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Activity through Acetylation
  • Regulation of TP53 Activity through Methylation
  • PI5P Regulates TP53 Acetylation
  • Activation of the TFAP2 (AP-2) family of transcription factors
  • RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function
  • RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known
  • RUNX3 regulates NOTCH signaling
  • RUNX3 regulates NOTCH signaling
  • Regulation of RUNX3 expression and activity
  • RUNX3 regulates p14-ARF
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH3 Intracellular Domain Regulates Transcription
  • NOTCH4 Intracellular Domain Regulates Transcription
  • Estrogen-dependent gene expression
  • NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux
  • NGF-stimulated transcription
  • NGF-stimulated transcription
  • TRAF3-dependent IRF activation pathway
  • TRAF6 mediated IRF7 activation
  • FOXO-mediated transcription of cell death genes
  • Transcriptional regulation of granulopoiesis
  • Transcriptional regulation of granulopoiesis
  • Regulation of FOXO transcriptional activity by acetylation
  • Regulation of FOXO transcriptional activity by acetylation
  • STAT3 nuclear events downstream of ALK signaling
  • Heme signaling
  • SARS-CoV-1 targets host intracellular signalling and regulatory pathways
  • Nuclear events mediated by NFE2L2
  • Formation of paraxial mesoderm
  • NFE2L2 regulating inflammation associated genes
  • NFE2L2 regulating anti-oxidant/detoxification enzymes
  • NFE2L2 regulates pentose phosphate pathway genes
  • NFE2L2 regulating tumorigenic genes
  • NFE2L2 regulating MDR associated enzymes
  • NFE2L2 regulating ER-stress associated genes
  • Regulation of NFE2L2 gene expression
  • Regulation of NFE2L2 gene expression
  • Zygotic genome activation (ZGA)
  • Evasion by RSV of host interferon responses
  • TGFBR3 expression
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • Regulation of PD-L1(CD274) transcription
  • Expression of BMAL (ARNTL), CLOCK, and NPAS2
  • RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression
  • Rubinstein-Taybi syndrome
F2 coagulation factor II, thrombin
  • Intrinsic Pathway of Fibrin Clot Formation
  • Common Pathway of Fibrin Clot Formation
  • Gamma-carboxylation of protein precursors
  • Transport of gamma-carboxylated protein precursors from the endoplasmic reticulum to the Golgi apparatus
  • Removal of aminoterminal propeptides from gamma-carboxylated proteins
  • Cell surface interactions at the vascular wall
  • Peptide ligand-binding receptors
  • Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
  • G alpha (q) signalling events
  • Thrombin signalling through proteinase activated receptors (PARs)
  • Platelet Aggregation (Plug Formation)
  • Defective factor XII causes hereditary angioedema
  • Defective F8 cleavage by thrombin
  • Regulation of Complement cascade
  • Lepirudin
  • Bivalirudin
  • Drotrecogin alfa
  • Coagulation Factor IX (Recombinant)
  • Menadione
  • Argatroban
  • Proflavine
  • Enoxaparin
  • Zinc
  • 2-{2-hydroxy-[1,1'-biphenyl]-3-yl}-1H-1,3-benzodiazole-5-carboximidamide
  • Beta-(2-Naphthyl)-Alanine
  • Hemi-Babim
  • 2-(2-hydroxy-phenyl)-3H-benzoimidazole-5-carboxamidine
  • 4-Oxo-2-Phenylmethanesulfonyl-Octahydro-Pyrrolo[1,2-a]Pyrazine-6-Carboxylic Acid [1-(N-Hydroxycarbamimidoyl)-Piperidin-4-Ylmethyl]-Amide
  • 4-Iodobenzo[B]Thiophene-2-Carboxamidine
  • CRA_8696
  • gamma-carboxy-L-glutamic acid
  • 6-Chloro-2-(2-Hydroxy-Biphenyl-3-Yl)-1h-Indole-5-Carboxamidine
  • Lysophosphotidylserine
  • N-{2,2-DIFLUORO-2-[(2R)-PIPERIDIN-2-YL]ETHYL}-2-[2-(1H-1,2,4-TRIAZOL-1-YL)BENZYL][1,3]OXAZOLO[4,5-C]PYRIDIN-4-AMINE
  • TRANS-4-(GUANIDINOMETHYL)-CYCLOHEXANE-L-YL-D-3-CYCLOHEXYLALANYL-L-AZETIDINE-2-YL-D-TYROSINYL-L-HOMOARGININAMIDE
  • 2-[3-chloro-6-[2,2-difluoro-2-(1-oxidopyridin-1-ium-2-yl)ethyl]imino-1-hydroxypyridin-2-yl]-N-[(1R)-1-(3-chlorophenyl)ethyl]acetamide
  • 1-GUANIDINO-4-(N-NITRO-BENZOYLAMINO-L-LEUCYL-L-PROLYLAMINO)BUTANE
  • 1-GUANIDINO-4-(N-PHENYLMETHANESULFONYL-L-LEUCYL-L-PROLYLAMINO)BUTANE
  • Suramin
  • Ximelagatran
  • Flovagatran
  • Thrombomodulin Alfa
  • Human C1-esterase inhibitor
  • Dabigatran etexilate
  • methyl L-phenylalaninate
  • [(2R)-1-[(2S)-2-[[(2S,3S)-1-Chloro-6-(diaminomethylideneamino)-2-hydroxyhexan-3-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]azanium
  • (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentylamino)ethanoyl)pyrrolidine-2-carboxamide
  • (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexylamino)ethanoyl)pyrrolidine-2-carboxamide
  • N-cycloheptylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
  • N-cyclooctylglycyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
  • N-ALLYL-5-AMIDINOAMINOOXY-PROPYLOXY-3-CHLORO-N-CYCLOPENTYLBENZAMIDE
  • 6-(2-HYDROXY-CYCLOPENTYL)-7-OXO-HEPTANAMIDINE
  • 6-CARBAMIMIDOYL-2-[2-HYDROXY-6-(4-HYDROXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID
  • 6-CARBAMIMIDOYL-2-[2-HYDROXY-5-(3-METHOXY-PHENYL)-INDAN-1-YL]-HEXANOIC ACID
  • N-(3-chlorobenzyl)-1-(4-methylpentanoyl)-L-prolinamide
  • 1-[2-AMINO-2-CYCLOHEXYL-ACETYL]-PYRROLIDINE-3-CARBOXYLIC ACID 5-CHLORO-2-(2-ETHYLCARBAMOYL-ETHOXY)-BENZYLAMIDE
  • 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide
  • D-leucyl-N-(3-chlorobenzyl)-L-prolinamide
  • D-phenylalanyl-N-(3-chlorobenzyl)-L-prolinamide
  • 1-butanoyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
  • N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide
  • N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide
  • 1-[(2R)-2-aminobutanoyl]-N-(4-carbamimidoylbenzyl)-L-prolinamide
  • D-leucyl-N-(4-carbamimidoylbenzyl)-L-prolinamide
  • D-phenylalanyl-N-{4-[amino(iminio)methyl]benzyl}-L-prolinamide
  • (3R)-8-(dioxidosulfanyl)-3-methyl-1,2,3,4-tetrahydroquinoline
  • D-phenylalanyl-N-(3-fluorobenzyl)-L-prolinamide
  • beta-phenyl-D-phenylalanyl-N-propyl-L-prolinamide
  • (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclopentyloxy)ethanoyl)pyrrolidine-2-carboxamide
  • (S)-N-(4-carbamimidoylbenzyl)-1-(2-(cyclohexyloxy)ethanoyl)pyrrolidine-2-carboxamide
  • (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide
  • 2-[2-(4-Chloro-Phenylsulfanyl)-Acetylamino]-3-(4-Guanidino-Phenyl)-Propionamide
  • 3-Carbamimidamido-1,1-diphenylurea
  • N7-BUTYL-N2-(5-CHLORO-2-METHYLPHENYL)-5-METHYL[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE-2,7-DIAMINE
  • (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclohexylpropanoyl)pyrrolidine-2-carboxamide
  • D-phenylalanyl-N-(3-methylbenzyl)-L-prolinamide
  • D-phenylalanyl-N-benzyl-L-prolinamide
  • N-(5-CHLORO-BENZO[B]THIOPHEN-3-YLMETHYL)-2-[6-CHLORO-OXO-3-(2-PYRIDIN-2-YL-ETHYLAMINO)-2H-PYRAZIN-1-YL]-ACETAMIDE
  • 3-cyclohexyl-D-alanyl-N-(3-chlorobenzyl)-L-prolinamide
  • (2R)-2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}PROPENE-1-SULFONAMIDE
  • 2-(5-CHLORO-2-THIENYL)-N-{(3S)-1-[(1S)-1-METHYL-2-MORPHOLIN-4-YL-2-OXOETHYL]-2-OXOPYRROLIDIN-3-YL}ETHANESULFONAMIDE
  • GW-813893
  • N-ETHYL-N-ISOPROPYL-3-METHYL-5-{[(2S)-2-(PYRIDIN-4-YLAMINO)PROPYL]OXY}BENZAMIDE
  • 4-(2,5-DIAMINO-5-HYDROXY-PENTYL)-PHENOL
  • 2-[N'-(4-AMINO-BUTYL)-HYDRAZINOCARBONYL]-PYRROLIDINE-1-CARBOXYLIC ACID BENZYL ESTER
  • 5-(DIMETHYLAMINO)-1-NAPHTHALENESULFONIC ACID(DANSYL ACID)
  • 1-ETHOXYCARBONYL-D-PHE-PRO-2(4-AMINOBUTYL)HYDRAZINE
  • 4-TERT-BUTYLBENZENESULFONIC ACID
  • 3-AMINO-3-BENZYL-9-CARBOXAMIDE[4.3.0]BICYCLO-1,6-DIAZANONAN-2-ONE
  • 4-(5-BENZENESULFONYLAMINO-1-METHYL-1H-BENZOIMIDAZOL-2-YLMETHYL)-BENZAMIDINE
  • 1-(2-{[(6-amino-2-methylpyridin-3-yl)methyl]amino}ethyl)-6-chloro-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-1,4-dihydropyrazin-2-ol
  • (3Z,6S)-6-Chloro-1-(2-{[(5-chloro-1-benzothiophen-3-yl)methyl]amino}ethyl)-3-({2-[(2R)-2-piperidinyl]ethyl}imino)-2-piperazinol
  • N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]NAPHTHALENE-2-SULFONAMIDE
  • N-[(2R,3S)-3-AMINO-2-HYDROXY-4-PHENYLBUTYL]-4-METHOXY-2,3,6-TRIMETHYLBENZENESULFONAMIDE
  • 2-(6-Chloro-3-{[2,2-difluoro-2-(2-pyridinyl)ethyl]amino}-2-oxo-1(2H)-pyrazinyl)-N-[(2-fluoro-6-pyridinyl)methyl]acetamide
  • 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUORO-3-METHYL-6-PYRIDINYL)METHYL]ACETAMIDE
  • 2-(6-CHLORO-3-{[2,2-DIFLUORO-2-(1-OXIDO-2-PYRIDINYL)ETHYL]AMINO}-2-OXO-1(2H)-PYRAZINYL)-N-[(2-FLUOROPHENYL)METHYL]ACETAMIDE
  • 3-(7-DIAMINOMETHYL-NAPHTHALEN-2-YL)-PROPIONIC ACID ETHYL ESTER
  • AC-(D)Phe-pro-borolys-OH
  • AC-(D)PHE-PRO-BOROHOMOLYS-OH
  • AC-(D)PHE-PRO-BOROHOMOORNITHINE-OH
  • N-[2-(carbamimidamidooxy)ethyl]-2-{6-cyano-3-[(2,2-difluoro-2-pyridin-2-ylethyl)amino]-2-fluorophenyl}acetamide
  • 4-Hydroxyphenylpyruvic acid
  • 4-(1R,3AS,4R,8AS,8BR)-[1-DIFLUOROMETHYL-2-(4-FLUOROBENZYL)-3-OXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZAMIDINE
  • (3ASR,4RS,8ASR,8BRS)-4-(2-(4-FLUOROBENZYL)-1,3-DIOXODEACAHYDROPYRROLO[3,4-A] PYRROLIZIN-4-YL)BENZAMIDINE
  • 4-({[4-(3-METHYLBENZOYL)PYRIDIN-2-YL]AMINO}METHYL)BENZENECARBOXIMIDAMIDE
  • 1-(HYDROXYMETHYLENEAMINO)-8-HYDROXY-OCTANE
  • [[CYCLOHEXANESULFONYL-GLYCYL]-3[PYRIDIN-4-YL-AMINOMETHYL]ALANYL]PIPERIDINE
  • N-{3-METHYL-5-[2-(PYRIDIN-4-YLAMINO)-ETHOXY]-PHENYL}-BENZENESULFONAMIDE
  • N-[2-({[amino(imino)methyl]amino}oxy)ethyl]-2-{6-chloro-3-[(2,2-difluoro-2-phenylethyl)amino]-2-fluorophenyl}acetamide
  • 4-[3-(4-CHLOROPHENYL)-1H-PYRAZOL-5-YL]PIPERIDINE
  • 3-(4-CHLOROPHENYL)-5-(METHYLTHIO)-4H-1,2,4-TRIAZOLE
  • {(2S)-1-[N-(tert-butoxycarbonyl)glycyl]pyrrolidin-2-yl}methyl (3-chlorophenyl)acetate
  • N-Methylphenylalanyl-N-[(trans-4-aminocyclohexyl)methyl]-L-prolinamide
  • 2-Naphthalenesulfonic acid
  • [PHENYLALANINYL-PROLINYL]-[2-(PYRIDIN-4-YLAMINO)-ETHYL]-AMINE
  • 4-[(3AS,4R,7R,8AS,8BR)-2-(1,3-BENZODIOXOL-5-YLMETHYL)-7-HYDROXY-1,3-DIOXODECAHYDROPYRROLO[3,4-A]PYRROLIZIN-4-YL]BENZENECARBOXIMIDAMIDE
  • 1-[(4S)-4-amino-5-(1,3-benzothiazol-2-yl)-5-oxopentyl]guanidine
  • Turoctocog alfa
  • Copper
  • Conestat alfa
  • Kappadione
  • Antithrombin Alfa
  • Nafamostat
  • Gabexate
  • Anti-inhibitor coagulant complex
  • Coagulation Factor IX Human
  • Zinc acetate
  • Turoctocog alfa pegol
  • Inherited thrombophilia
FKBP1A FKBP prolyl isomerase 1A
  • mTORC1-mediated signalling
  • Calcineurin activates NFAT
  • Calcineurin activates NFAT
  • TGF-beta receptor signaling activates SMADs
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • TGFBR1 LBD Mutants in Cancer
  • Potential therapeutics for SARS
  • SARS-CoV-1 activates/modulates innate immune responses
  • Pimecrolimus
  • Tacrolimus
  • (3R)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-L-phenylalanine ethyl ester
  • {3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid
  • Gpi-1046
  • Methyl Methylsulfinylmethyl Sulfide
  • FKB-001
  • Heptyl glucoside
  • L-709,587
  • (3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine
  • 4-hydroxybutan-2-one
  • GPI-1485
  • Myristic acid
  • (21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE
  • Dorsomorphin
FYN FYN proto-oncogene, Src family tyrosine kinase
  • GPVI-mediated activation cascade
  • Signaling by ERBB2
  • PIP3 activates AKT signaling
  • Signaling by SCF-KIT
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Nef and signal transduction
  • Cell surface interactions at the vascular wall
  • FCGR activation
  • PECAM1 interactions
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • DAP12 signaling
  • DAP12 signaling
  • EPH-Ephrin signaling
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Nephrin family interactions
  • Nephrin family interactions
  • NCAM signaling for neurite out-growth
  • NCAM signaling for neurite out-growth
  • Co-stimulation by CD28
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • Co-inhibition by CTLA4
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • EPHA-mediated growth cone collapse
  • EPHA-mediated growth cone collapse
  • Ephrin signaling
  • Ephrin signaling
  • EPH-ephrin mediated repulsion of cells
  • Sema3A PAK dependent Axon repulsion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion
  • CRMPs in Sema3A signaling
  • CRMPs in Sema3A signaling
  • VEGFA-VEGFR2 Pathway
  • Dectin-2 family
  • CD209 (DC-SIGN) signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Platelet Adhesion to exposed collagen
  • Reelin signalling pathway
  • Regulation of signaling by CBL
  • Regulation of signaling by CBL
  • FCGR3A-mediated IL10 synthesis
  • FCGR3A-mediated phagocytosis
  • Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
  • Signaling by CSF1 (M-CSF) in myeloid cells
  • FLT3 signaling through SRC family kinases
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells
  • Dasatinib
  • Triglyme
  • Fostamatinib
  • Zotiraciclib
GSK3A glycogen synthase kinase 3 alpha
  • AKT phosphorylates targets in the cytosol
  • XBP1(S) activates chaperone genes
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Suppression of apoptosis
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
  • Fostamatinib
GSK3B glycogen synthase kinase 3 beta
  • Degradation of beta-catenin by the destruction complex
  • Beta-catenin phosphorylation cascade
  • AKT phosphorylates targets in the cytosol
  • Regulation of HSF1-mediated heat shock response
  • CRMPs in Sema3A signaling
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Disassembly of the destruction complex and recruitment of AXIN to the membrane
  • B-WICH complex positively regulates rRNA expression
  • Signaling by GSK3beta mutants
  • CTNNB1 S33 mutants aren't phosphorylated
  • CTNNB1 S37 mutants aren't phosphorylated
  • CTNNB1 S45 mutants aren't phosphorylated
  • CTNNB1 T41 mutants aren't phosphorylated
  • APC truncation mutants have impaired AXIN binding
  • AXIN missense mutants destabilize the destruction complex
  • Truncations of AMER1 destabilize the destruction complex
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Constitutive Signaling by AKT1 E17K in Cancer
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Ubiquitin-dependent degradation of Cyclin D
  • Regulation of RUNX2 expression and activity
  • Maturation of nucleoprotein
  • Maturation of nucleoprotein
  • GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
  • Transcriptional and post-translational regulation of MITF-M expression and activity
  • GSK3B-mediated proteasomal degradation of PD-L1(CD274)
  • Lithium cation
  • 3-[3-(2,3-Dihydroxy-Propylamino)-Phenyl]-4-(5-Fluoro-1-Methyl-1h-Indol-3-Yl)-Pyrrole-2,5-Dione
  • SB-409513
  • AR-AO-14418
  • Staurosporine
  • Indirubin-3'-monoxime
  • 6-bromoindirubin-3'-oxime
  • Alsterpaullone
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 2-(1,3-benzodioxol-5-yl)-5-[(3-fluoro-4-methoxybenzyl)sulfanyl]-1,3,4-oxadiazole
  • 5-[1-(4-methoxyphenyl)-1H-benzimidazol-6-yl]-1,3,4-oxadiazole-2(3H)-thione
  • (7S)-2-(2-aminopyrimidin-4-yl)-7-(2-fluoroethyl)-1,5,6,7-tetrahydro-4H-pyrrolo[3,2-c]pyridin-4-one
  • N-[2-(5-methyl-4H-1,2,4-triazol-3-yl)phenyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine
  • 5-(5-chloro-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine
  • 3-({[(3S)-3,4-dihydroxybutyl]oxy}amino)-1H,2'H-2,3'-biindol-2'-one
  • N-[(1S)-2-amino-1-phenylethyl]-5-(1H-pyrrolo[2,3-b]pyridin-4-yl)thiophene-2-carboxamide
  • 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE
  • ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE
  • (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE
  • Fostamatinib
  • Tideglusib
  • Lithium citrate
  • Lithium succinate
  • Lithium carbonate

Page 2 out of 7 pages